IGF1 and acromegaly: In a prospective, open-label study of patients with acromegaly who switched from short-acting subcutaneous octreotide to intramuscular depot octreotide injections, IGF-I was in the normal range in 63.1% of patients before the switch and 65.8% of patients afterward (24).